Australia-based Immuron has entered a research and development collaboration agreement with the Naval Medical Research Center to test the bio-pharmaceutical company’s drug against gastrointestinal problems.
The company said Aug. 30 it will test the Travelan dietary supplement against Campylobacter and Enterotoxigenic Escherichia coli gram-negative bacteria to help develop therapeutics in an effort to protect military and civilian populations from diarrhea.
Immuron and NMRC researchers will carry out the tests under an Investigational New Drug application with the Food and Drug Administration in efforts to gain approvals for campylobacter and ETEC vaccine-based products.
Travelan contains the Immuron-developed Hyperimmune Bovine Colostrum Powder which is a source of antibodies that work to neutralize the ability of Enterotoxigenic E. coli to cause travelers’ diarrhea and its symptoms.
Immuron partnered with the U.S. Army‘s Walter Reed Army Institute of Research in June to create a shigella vaccine to protect against intestinal diseases.